Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 5/20 | 0.51 |
| ▸ | NPY1R | P25929 | 3/20 | 0.51 |
| ▸ | NPY2R | P49146 | 3/20 | 0.51 |
| ▸ | NPY4R | P50391 | 3/20 | 0.51 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30390841 | 0.94 | NPY4R (0.58) | NPY1RNPY2RNPY4RKISS1ROPRM1 | |
| SCHEMBL31206184 | 0.93 | KISS1R (0.55) | GHSRKISS1ROPRM1OPRD1 | |
| SCHEMBL30259958 | 0.93 | GHSR (0.55) | GHSRNPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL30451792 | 0.92 | NPBWR1 (0.52) | GHSRNPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL30669192 | 0.92 | NPY1R (0.57) | NPY1RNPY2RNPY4RKISS1ROPRM1 | |
| SCHEMBL31073545 | 0.92 | GHSR (0.55) | GHSRNPBWR1 | |
| SCHEMBL30839329 | 0.91 | KDM4E (0.53) | GHSRKISS1R | |
| SCHEMBL30919241 | 0.90 | KISS1R (0.55) | GHSRNPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL30919236 | 0.90 | KISS1R (0.55) | GHSRNPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL29799999 | 0.90 | KDM4E (0.52) | GHSRNPY1RNPY2RNPY4RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203096-A1 | EPHA4 TARGETING COMPOUNDS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-29 | — | — | US | disclosed |
| EP-4139326-A1 | EPHA4 TARGETING COMPOUNDS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203096-A1 | EPHA4 TARGETING COMPOUNDS AND METHODS OF USE THEREOF | EPHA4, EPHA1, EPHA5 | GHSR 4150/4885NPY1R 2313/4885NPY2R 2482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.